BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tyler-Stone Wealth Management | 52 | $4 | 0.00% |
| Glassman Wealth Services | 146 | $9,938 | 0.00% |
| VICTORY CAPITAL MANAGEMENT INC | 31,360 | $2,134,675 | 0.00% |
| Bell Investment Advisors, Inc | 154 | $10,483 | 0.00% |
| Creative Planning | 26,896 | $1,830,811 | 0.00% |
| LPL Financial LLC | 40,412 | $2,728,817 | 0.00% |
| CENTRAL TRUST Co | 988 | $67,254 | 0.00% |
| Corient Private Wealth LLC | 13,832 | $941,562 | 0.00% |
| BNP PARIBAS FINANCIAL MARKETS | 231 | $1,572,417 | 0.00% |
| UniSuper Management Pty Ltd | 2,324 | $158,195 | 0.00% |
| TRUIST FINANCIAL CORP | 20,077 | $1,366,616 | 0.00% |
| ROCKY MOUNTAIN ADVISERS, LLC | 52 | $3,540 | 0.00% |
| Sands Capital Management | 9,530 | $648,707 | 0.00% |
| GREENLEAF TRUST | 3,036 | $206,661 | 0.00% |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 10,276 | $699,487 | 0.00% |
| COMMONWEALTH EQUITY SERVICES, LLC | 15,716 | $1,070 | 0.00% |
| Steward Partners Investment Advisory, LLC | 1,812 | $123,343 | 0.00% |
| CREDIT AGRICOLE S A | 1,481 | $100,812 | 0.00% |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 3,647 | $248,251 | 0.00% |
| Raymond James Financial Services Advisors, Inc. | 4,354 | $296,348 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.